Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Acquires $21,818.65 in Stock

by · The Markets Daily

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report) major shareholder Financial Lp Hrt purchased 6,755 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was bought at an average cost of $3.23 per share, with a total value of $21,818.65. Following the completion of the acquisition, the insider owned 78,597 shares of the company’s stock, valued at approximately $253,868.31. The trade was a 9.40% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

  • On Monday, June 29th, Financial Lp Hrt acquired 25,836 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average cost of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

Shuttle Pharmaceuticals stock traded up $0.15 during midday trading on Wednesday, reaching $3.40. 169,219 shares of the company were exchanged, compared to its average volume of 2,351,062. The company has a market capitalization of $2.18 million, a price-to-earnings ratio of -0.07 and a beta of 0.29. The firm’s 50-day simple moving average is $5.93 and its 200-day simple moving average is $10.74. Shuttle Pharmaceuticals Holdings, Inc. has a 1 year low of $2.90 and a 1 year high of $55.90.

Shuttle Pharmaceuticals (NASDAQ:SHPH – Get Free Report) last released its earnings results on Tuesday, March 31st. The company reported $0.60 earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Shuttle Pharmaceuticals presently has a consensus rating of “Sell”.

Check Out Our Latest Analysis on Shuttle Pharmaceuticals

Institutional Trading of Shuttle Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC acquired a new position in shares of Shuttle Pharmaceuticals during the 4th quarter valued at about $26,000. Boothbay Fund Management LLC purchased a new stake in Shuttle Pharmaceuticals in the fourth quarter valued at approximately $37,000. Ikarian Capital LLC purchased a new stake in Shuttle Pharmaceuticals in the fourth quarter valued at approximately $124,000. Finally, Connective Capital Management LLC acquired a new position in Shuttle Pharmaceuticals during the third quarter worth approximately $357,000. 4.58% of the stock is owned by institutional investors and hedge funds.

Shuttle Pharmaceuticals Company Profile

(Get Free Report)

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .

Read More